Eric Heil, MBA, is a venture capital investor turned entrepreneur turned venture capitalist again with extensive experience across the healthcare industry. He currently serves as the managing partner at Medical Excellence Capital, LLC, a $150M early stage life science venture fund founded by patients for patients. He holds board positions at Nobias Therapeutics and GC Therapeutics and is the co-founder and board chair of ProJenX, a company focused on therapies for brain diseases like ALS.
He also serves as a board advisor to the Medical Excellence Foundation, a 501c3 non-profit organization, and is an active member of the Faith-Driven Investor movement. Prior to his current role, Eric cofounded and led two venture-backed companies, including Upward Health and RightCare. Eric began his career in venture capital as an investment professional at Domain Associates, LLC, the oldest biotech focused venture fund in the country. Eric’s academic background includes a bachelor’s in systems engineering from the University of Pennsylvania and an MBA from Wharton. He currently resides in Bucks County, PA with his family of 5 children.
Kathie Jordan is the managing director of the Healthcare Investment Group at Ben Franklin Technology Partners, Southeast, where she leads an investment portfolio of 70+ early stage companies. She was previously at Drexel University, where she led the Coulter-Drexel Translational Research Partnership, an endowed non-dilutive fund of health care technologies, ranging from small molecule therapeutics to medical devices and diagnostics. Technologies that were initially supported by the program have been licensed to over a dozen startups, with multiple products now on the market.
Prior to joining Drexel, she was the director of the Coulter program at the University of Washington, where she also worked in the technology transfer office. She has served as a speaker, panelist and moderator on the topic of university technology commercialization in the life science space, and was an adviser to the C3i program, which trains early-stage biomedical project teams in the commercialization of their innovations, and has been a reviewer for NSF, NIH, and the Flinn Foundation. Kathie spent her early career studying drosophila ovarian development and the role of the innate immune pathways in mouse and endothelial models of sepsis. She has a PhD in molecular and cellular biology from the University of Washington and a BS in biology with honors from Haverford College.
Mohamed Kashkoush, PharmD
Mohamed Kashkoush is the Associate Director of the Strategic Initiatives Group within Daiichi Sankyo’s Global Business Development organization, where he focuses on Daiichi Sankyo’s venture capital relationships and strategic ecosystem engagements.
In addition to managing Daiichi Sankyo’s existing partnership with Hatch Biofund, he identifies new technology partnerships to support Daiichi Sankyo’s precision medicine efforts. Mohamed was previously responsible for search & evaluation initiatives ranging from early-stage drug discovery technologies through late-stage clinical therapeutics.